# KPV: research reference

For research use only. Checked November 1, 2026.

KPV is the tripeptide Lys–Pro–Val. Primary research has examined its transport into cells, inflammatory signaling in laboratory systems, and delivery through engineered formulations in animal colitis models. These are related but distinct questions. A result with a specialized nanoparticle or hydrogel cannot automatically be assigned to unformulated KPV, another preparation, or a commercial vial. The selected work does not establish a human-use conclusion.

## Identity
A three-letter sequence is a useful starting point, not a complete analytical specification. Confirm stereochemistry, terminal form, salt/counterion, material purity and content basis for the sample. If a study uses KPV inside a carrier, the carrier and release behavior are part of the experimental intervention.

## Mechanism
Dalmasso and colleagues investigated uptake involving the PepT1 di/tripeptide transporter, alongside NF-κB/MAP-kinase-related inflammatory measurements in epithelial and immune-cell systems and mouse experiments. This supports a transport-and-signaling research question rather than a universal anti-inflammatory claim. [kpv-2008]

Subsequent work examined nanoparticle/hydrogel delivery and later hyaluronic-acid-functionalized carriers. The materials were designed to change access to the experimental target. Delivery-platform findings should remain attached to their tested formulations. [kpv-2010, kpv-2017]

A useful reading sequence is identity → transport → tissue exposure → measured endpoint. Skipping the middle steps can make a formulation result appear to be an intrinsic property of every KPV product.

## Selected research
### Transporter-linked uptake
Model: Human-derived intestinal/immune cell systems and two mouse colitis models

The study reported PepT1-mediated uptake and changes in inflammatory signaling and experimental disease measurements.

Limitation: Cell-line and mouse-model findings do not establish clinical effectiveness or describe all biological settings.

### Carrier matters
Model: Cell experiments and DSS-induced mouse colitis using KPV-loaded nanoparticles in a hydrogel

The engineered preparation changed experimental delivery and inflammatory/histologic measurements compared with the study controls.

Limitation: The result applies to a delivery system, not automatically to free peptide or a different carrier.

### Targeted formulation research
Model: Cell uptake work and a mouse colitis model using hyaluronic-acid-functionalized nanoparticles

Investigators assessed cell targeting and tissue/inflammatory endpoints with a specialized KPV delivery formulation.

Limitation: A multicomponent formulation and animal model cannot validate a commercial product bearing the KPV name.

## Open questions
- Which effects reproduce independently across cell types, experimental models and analytical specifications?
- How much of an observed result depends on the peptide, the carrier or the combination?
- What applicable human evidence exists for the precise question being asked? These selected preclinical papers do not answer it.
- No systematic or exhaustive evidence search is claimed here.

## Storage and handling
Carrier-system performance is not a universal storage-stability result. Preserve the distinction between free peptide, dry material, solutions and engineered formulations.

Follow documentation for the exact material and packaging; no general shelf life or solution-use period is established in this reference.

For research use only. No administration or formulation-preparation instructions are supplied.

## Sources
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (2008). https://pubmed.ncbi.nlm.nih.gov/18061177/
- Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model (2010). https://pubmed.ncbi.nlm.nih.gov/19909746/
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis (2017). https://pubmed.ncbi.nlm.nih.gov/28143741/

Primary abstracts and metadata checked November 1, 2026. Findings are explicitly preclinical and formulation-specific. No complete clinical review or independent scientific review is claimed.